Место антагонистов минералокортикоидных рецепторов в лечении хронической сердечной недостаточности

Орлова Н.В., Спирякина Я.Г. Место антагонистов минералокортикоидных рецепторов в лечении хронической сердечной недостаточности. Consilium Medicum. 2018; 20 (10): 36–40. DOI: 10.26442/2075-1753_2018.10.36-40

________________________________________________

Orlova N.V., Spiryakina Ya.G. The place of antagonists of mineralocorticoid receptors in the treatment of chronic heart failure. Consilium Medicum. 2018; 20 (10): 36–40. DOI: 10.26442/2075-1753_2018.10.36-40

Читать PDF

Аннотация

Хроническая сердечная недостаточность приобрела масштабы современной эпидемии. В статье рассматриваются вопросы применения антагонистов минералокортикоидных рецепторов как препаратов, улучшающих выживаемость и качество жизни пациентов с хронической сердечной недостаточностью, обсуждаются возможные сложности назначения, пути их преодоления, выбор конкретного препарата и возможности повышения приверженности пациентов лечению.

Ключевые слова: хроническая сердечная недостаточность, антагонисты минералокортикоидных рецепторов, эплеренон, приверженность терапии.

________________________________________________

Chronic heart failure is the modern epidemic. The article discusses the use of antagonists of mineralocorticoid receptors as drugs that improve the survival and quality of life of patients with chronic heart failure, discusses the possible complexity of the appointment, the ways to overcome them, the choice of a particular drug and the possibility of increasing patient adherence to treatment.

Key words: chronic heart failure, antagonists of mineralocorticoid receptors, eplerenone, adherence to therapy.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113 (6): 646–59.

2. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017; 18 (1): 3–40. / Mareev V.Iu., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Serdechnaia nedostatochnost'. 2017; 18 (1): 3–40. [in Russian]
3. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17.
4. Prabhash C Manoria, Pankaj Manoria, Nidhi Mishra. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertension 2016; 2 (3): 145–52.
5. Duprez D, De Buyzere M, Rietzschel ER et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327–34.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–65.
7. Chai W, Garrelds IM, de Vries R et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005; 46: 701–6.
8. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
9. Pitt B, Remme W, Zannad F et al. Eplerenone, aselective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
10. Zannad F, McMurray JJV, Henry Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11–21.
11. Dev S, Hoffman TK, Kavalieratos D et al. Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. Am Heart Assoc 2016; 5: e002493
12. Curtis LH, Mi X, Qualls LG et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013; 165: 979–86.
13. Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (27): 2129–200.

________________________________________________

1. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113 (6): 646–59.
2. Mareev V.Iu., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Serdechnaia nedostatochnost'. 2017; 18 (1): 3–40. [in Russian]
3. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17.
4. Prabhash C Manoria, Pankaj Manoria, Nidhi Mishra. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertension 2016; 2 (3): 145–52.
5. Duprez D, De Buyzere M, Rietzschel ER et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327–34.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–65.
7. Chai W, Garrelds IM, de Vries R et al. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension 2005; 46: 701–6.
8. Sato A, Saruta T. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
9. Pitt B, Remme W, Zannad F et al. Eplerenone, aselective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
10. Zannad F, McMurray JJV, Henry Krum H et al. for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11–21.
11. Dev S, Hoffman TK, Kavalieratos D et al. Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. Am Heart Assoc 2016; 5: e002493
12. Curtis LH, Mi X, Qualls LG et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013; 165: 979–86.
13. Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (27): 2129–200.

Авторы

Н.В.Орлова, Я.Г.Спирякина*

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*janezo@yandex.ru

________________________________________________

N.V.Orlova, Ya.G.Spiryakina*

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*janezo@yandex.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.